How Your Accumulated Shot Tolerance Carries Over When You Switch to Sublingual Drops

At-home sublingual immunotherapy can be an alternative for patients who cannot sustain allergy shots, and switching does not necessarily mean starting over. The immune tolerance built during shots provides a biological foundation that drops can build on. For patients who have completed shot build-up, an ASBAI transition protocol allows maintenance-level sublingual dosing from the outset, though the starting dose remains a decision to make with a clinician.

Why patients with meaningful shot progress abandon immunotherapy before it finishes working

The shots may be helping, but the appointments have become hard to sustain. Each visit competes with work, family commitments, and the rest of daily life. Over time, the schedule can become the reason a patient stops, even when symptoms have improved. The treatment worked better than the delivery format did.

Is the problem immunotherapy itself, or the way it fits into life? A meaningful share of shot patients leave before reaching or completing maintenance, when treatment is meant to deepen the immune changes already underway. Yet that progress does not disappear at the clinic door. Stopping entirely leaves unfinished a process that another delivery route may help the patient continue.

What allergy shots are actually building inside the immune system

Feeling less congested is one outcome of treatment. Allergy shots, also called subcutaneous immunotherapy or SCIT, expose the immune system to specific allergens in controlled doses. While medicines relieve symptoms, allergen immunotherapy changes the immune response that causes them. Tolerance is a biological state.

That change takes repeated exposure over time. During build-up, patients generally receive one to two injections weekly, with escalating doses, for roughly 3–6 months. Maintenance then uses monthly injections over 3–5 years to sustain and deepen that training. The two phases serve different purposes. Reaching maintenance marks progress, but it is not the same as finishing treatment.

Inside the immune system, shots help develop cells that restrain the allergic response. These are T regulatory lymphocytes, or Tregs, which suppress the allergy-driving response known as Th2. Shots also encourage production of antibodies that intercept allergens before they trigger reactions mediated by an antibody involved in allergy. IgG4 is a particularly important blocking antibody.

Shots also change the signals immune cells exchange. They suppress Th2 cytokines while increasing IL-10 and TGF-β, signals associated with successful tolerance induction. Together, these changes describe a shift away from a reactive response dominated by an antibody involved in allergy toward an IgG4-associated, more tolerant response. A patient who has completed build-up has begun meaningful immune retraining, even though continued treatment is needed to strengthen it.

How sublingual drops produce tolerance through overlapping but distinct mechanisms

Sublingual immunotherapy, or SLIT, introduces allergens through the tissue under the tongue. Specialized cells in the mouth lining capture the allergen and present it to the immune system in a way that encourages tolerance. These are dendritic cells in the oral mucosa.

Like shots, drops encourage Tregs that suppress the allergic response. They also promote blocking antibodies, including IgG4 and IgA, and involve mucosal B cells as markers of clinical tolerance. Their effects include increases in IL-10 and TGF-β, the same signals linked to successful tolerance induction during shots.

The routes are not identical in every respect. Shots can produce a faster early decline in the activation of basophils, cells involved in allergic reactions, in some patients. Drops also work through the mouth’s immune tissues, where mucosal immunomodulation may build on the systemic tolerance that injections have established. A different route can therefore add a distinct influence. It need not erase the response built through the previous route.

Does this overlap prove that every switch will be seamless? A shared mechanism explains why changing delivery routes need not reset immune training, while leaving an individual patient’s dose and response unsettled. The same immune system is being guided toward the same tolerant state, with existing regulatory responses and blocking antibodies providing a foundation for continued treatment.

What clinical evidence says about switching from shots to drops mid-course

The evidence and protocols are not symmetrical in both directions. Completing shot build-up can support a head start when moving to drops, while moving from drops to shots during induction may require restarting build-up. The distinction is the treatment stage already reached. A patient still in SLIT induction has not necessarily developed the same depth of systemic tolerance that completed shot build-up establishes.

ASBAI’s transition protocol allows patients who have completed SCIT induction to begin SLIT at doses recommended for maintenance. It also recommends preferably using extracts from the same allergen supplier. This is a concrete clinical recognition of prior treatment. Under that protocol, the patient’s shot history changes where sublingual treatment can begin.

The recommendation has a clear boundary, however. It applies specifically to patients who have completed shot induction. Research supporting sustained improvement over a three-year SLIT course establishes that sublingual treatment can provide long-term immune modification. It does not, by itself, establish the exact benefit or transition dose for every shot-to-drops patient.

Some practitioners still restart build-up in either direction as a dosing safety precaution, even when previously developed tolerance may remain. The transition approach includes monthly monitoring, allowing clinical oversight rather than treating the switch as a simple product substitution. For a patient considering the change, the useful question is whether completed shot build-up supports maintenance-level SLIT under the treating clinician’s protocol.

What a shot-to-drops switcher should realistically expect in terms of timeline and symptom improvement

A switcher who begins at maintenance dosing avoids the escalating-dose period that a new SLIT patient would otherwise complete. The general benchmark for that build-up is roughly 3–6 months. This can shorten the path to the intended treatment dose. Symptoms may still take time to improve, and the rest of the course is still needed.

For new patients, noticeable improvement often begins within the first few months. Someone with prior shot tolerance may experience earlier stability, though the timetable remains uncertain. SLIT can meaningfully reduce allergic rhinoconjunctivitis symptoms, including nasal and eye symptoms, and reduce medication use. The patient is joining an effective treatment approach. How quickly that individual’s symptoms will settle after the route changes remains uncertain.

Long-term treatment still requires consistency. General maintenance benchmarks involve daily dosing for 3–5 years, and expert recommendations support prescribing SLIT for at least three years. Evidence supports benefits persisting for two to three years after a three-year course, with some studies observing longer effects. These findings apply to SLIT courses generally. A head start on dosing does not establish an interchangeable treatment calendar.

There is also a genuine durability trade-off. Drops can be as effective as shots, but tolerance after drops may not last as long after treatment ends. For someone unable to continue injections, the practical comparison may be between a sustainable drop course and an abandoned shot course.

Early side effects can include tingling or itching under the tongue, mild mouth swelling, and throat irritation. These are generally localized, brief reactions, occurring mostly during the first weeks. Systemic reactions are less likely than with shots. Lower risk, however, is not the same as no risk, and at-home treatment should not be understood as treatment without clinical oversight.

The cost of the gap: what happens to health during the years patients spend outside immunotherapy

A long break from immunotherapy can seem like a simple pause in treatment. Yet inadequately controlled allergic rhinitis affects more than sneezing and a runny nose. It can disrupt sleep and lead to daytime fatigue, depressed mood, irritability, and trouble thinking clearly. Those symptoms are easy to misread as general exhaustion. Their connection to allergies may be less obvious than an itchy nose.

Nasal congestion helps explain part of that connection. Nasal congestion can force a person to breathe through the mouth during sleep and break up their rest even when they seem to sleep a normal number of hours. Poor sleep then compounds the cognitive and mood effects of chronic allergic inflammation. The cost extends into the following day. A patient may be keeping obvious allergy symptoms under control while still living with effects that are harder to see.

First-generation antihistamines cross the blood-brain barrier and block histamine receptors in the central nervous system, causing sedation. They can also disrupt acetylcholine signaling, so the effects of the drug add to the fatigue caused by allergies. This criticism does not apply equally to every antihistamine. Medicines that relieve symptoms also leave out the allergen-specific immune training that immunotherapy provides.

House dust mite allergy raises a further concern because inadequately treated respiratory allergy can be associated with increased asthma risk. Immunotherapy aims to modify the disease process. Stopping treatment can have health consequences, including possible disease progression, especially when symptoms remain poorly controlled.

The distinction is between relief and continued disease modification. Medicines may help someone cope during a gap, but they do not complete the tolerance-building course that shots began. Meanwhile, disrupted sleep, fatigue, and poor concentration can keep extracting a daily cost. A patient who cannot sustain clinic visits may still have a workable route back to immunotherapy.

Can I switch from allergy shots to drops at home to finish treatment?

For patients whose main barrier is the injection schedule, drops change the part of treatment that made continuing difficult. Custom sublingual drops can combine multiple allergens, including pollen, dust mites, pet dander, and mold, in one daily dose taken at home. Routine dosing removes needles and repeated clinic trips. Convenience has a clinical purpose here because immunotherapy depends on sustained participation over years.

That convenience does not make completion automatic. Home treatment exchanges an appointment schedule for a daily routine. Its practical advantage depends on whether that routine is one the patient can maintain.

Drops are also not the only sublingual option. FDA-approved tablets include Grastek for Timothy grass, Ragwitek for ragweed, and Odactra for dust mites. These offer options for patients with a single well-defined allergen sensitivity, while custom drops can address multiple sensitivities in one formulation and allow dose adjustments based on response. The relevant comparison is therefore specific. Allergen coverage, dosing flexibility, treatment burden, and durability are more useful criteria than a universal ranking.

Telehealth-based care can make treatment easier to get through virtual consultations, at-home allergy testing, and treatment tailored to the patient and delivered to the door. Those services address the scheduling problem that may have driven the original dropout. They do not replace the clinical decision about the transition dose. The next step for a shot patient is a clinician-led transition discussion that accounts for completed build-up and finds a daily format the patient can sustain, so the immune foundation already established has a chance to become a completed course.